Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 528 participants.
Also called NCT02556450
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose other
- Phase
- Phase 2
- Enrolled
- 528 participants
- Sponsor
- Registry
-
NCT02556450
-
- Other papers using this trial's data
- Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF
- Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial
- The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial
- Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- France, Germany, Ireland, Italy, Netherlands, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02556450. Randomized; single masking; primary purpose other. Start 2016-01 (registry gives no type); primary completion 2018-09-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure
- Acronym
- Homage
- Condition
- Heart Failure
- Intervention (Drug)
- Spironolacton
- Lead sponsor
- ACS Biomarker
- Collaborator
- Institut National de la Santé Et de la Recherche Médicale, France
- Collaborator
- London School of Hygiene and Tropical Medicine
Record details
- Record id
cardio:ct-nct02556450- Content hash
371dc8122c0d3c86389a1a96f803f1104f62828ada115b97f4aff9f1f1cf3bb4